These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34162138)

  • 21. Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
    di Leandro L; Colasante M; Pitari G; Ippoliti R
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical studies with targeted toxins in malignant glioma.
    Rainov NG; Söling A
    Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide toxins directed at the matrix dissolution systems of cancer cells.
    Frankel AE; Bugge TH; Liu S; Vallera DA; Leppla SH
    Protein Pept Lett; 2002 Feb; 9(1):1-14. PubMed ID: 12141918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
    Hamamichi S; Fukuhara T; Hattori N
    Toxins (Basel); 2020 Oct; 12(10):. PubMed ID: 33076544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant immunotoxins in targeted cancer cell therapy.
    Reiter Y
    Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
    Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
    Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
    Kioi M; Seetharam S; Puri RK
    Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis.
    Brenner T; Steinberger I; Soffer D; Beraud E; Ben-Nun A; Lorberboum-Galski H
    Immunol Lett; 1999 Jun; 68(2-3):403-10. PubMed ID: 10424450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
    Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
    J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
    Lorberboum-Galski H
    Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant immunotoxins for cancer therapy.
    Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
    Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic effects of vascular smooth muscle cells of the chimeric toxin, heparin binding TGF alpha-Pseudomonas exotoxin.
    Fu YM; Mesri EA; Yu ZX; Kreitman RJ; Pastan I; Epstein SE
    Cardiovasc Res; 1993 Sep; 27(9):1691-7. PubMed ID: 8287449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
    Woodworth TG; Nichols JC
    Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of anti DLL4 Nanobody fused to truncated form of Pseudomonas exotoxin: As a novel immunotoxin to inhibit of cell proliferation and neovascularization.
    Mohammadlou M; Salehi S; Baharlou R
    Anal Biochem; 2022 Sep; 653():114776. PubMed ID: 35679954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotoxins and immunocytokines].
    Contet A; Caussanel V; Beck A; Lowe P
    Med Sci (Paris); 2019 Dec; 35(12):1054-1061. PubMed ID: 31903917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in anticancer immunotoxin therapy.
    Alewine C; Hassan R; Pastan I
    Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy.
    Nassiri M; Behnam-Rasouli R; Vakili-Azghandi M; Gopalan V; Dolati P; Nourmohammadi R
    Life Sci; 2022 Jan; 289():120222. PubMed ID: 34902436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.
    Li M; Mei S; Yang Y; Shen Y; Chen L
    Antib Ther; 2022 Jul; 5(3):164-176. PubMed ID: 35928456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.